◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Sino Biopharmaceutical Limited (1177) Financial History

Name: Sino Biopharmaceutical Limited (1177) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-09-22

Sino Biopharmaceutical Limited (1177) operates in the Biotechnology industry and is headquartered in Wan Chai, Hong Kong with about 22,838 employees. Its market capitalization is roughly HK$105 billion. In the fiscal year ended 2025-12-31, 1177 reported CNY 31.8B in revenue and CNY 2.3B in net income.

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others.

Interactive charts & full statements → Open the 1177 valuation workbench →

1177 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	CNY 31.8B	CNY 28.9B	CNY 26.2B	CNY 26.0B	—
Gross Profit	CNY 26.1B	CNY 23.5B	CNY 21.2B	CNY 21.5B	—
Operating Income (EBIT)	CNY 6.9B	CNY 6.3B	CNY 6.1B	CNY 5.5B	—
Net Income	CNY 2.3B	CNY 3.5B	CNY 2.3B	CNY 2.5B	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1177 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Dividends Paid	(CNY 1.5B)	(CNY 1.8B)	(CNY 633M)	(CNY 1.3B)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1177 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CNY 76.0B	CNY 65.4B	CNY 63.6B	CNY 64.1B	—
Total Liabilities	CNY 33.9B	CNY 22.6B	CNY 25.4B	CNY 26.1B	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1177 viewer.

Other Companies in Biotechnology

4587 · PeptiDream Inc. — JPY 138 billion
VRTX · Vertex Pharmaceuticals — $128 billion
6990 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — HK$114 billion
4565 · Nxera Pharma Co., Ltd. — JPY 111 billion
1548 · Genscript Biotech Corporation — HK$102 billion
9926 · Akeso, Inc. — HK$102 billion
BLUEJET · Blue Jet Healthcare Limited — ₹93 billion
MRNA · Moderna — $81 billion

← 1176 All “0-9” companies 1179 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.